{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:22:45Z","timestamp":1790623365644,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["IP.2007.31100.001"],"award-info":[{"award-number":["IP.2007.31100.001"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"name":"German Federal Ministry of Education and Research","award":["01KA0804"],"award-info":[{"award-number":["01KA0804"]}]},{"name":"German Federal Ministry of Education and Research","award":["01KA1402"],"award-info":[{"award-number":["01KA1402"]}]},{"name":"European Malaria Vaccine Initiative"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.vaccine.2016.07.041","type":"journal-article","created":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T16:43:43Z","timestamp":1469810623000},"page":"4536-4542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children"],"prefix":"10.1016","volume":"34","author":[{"given":"Sodiomon B.","family":"Sirima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Mordm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Milligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulysse Ateba","family":"Ngoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Kironde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Atuguba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred B.","family":"Tiono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadou","family":"Issifou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kaddumukasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Bangre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Flach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roma","family":"Chilengi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Jepsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Kremsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Theisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alphonse","family":"Ou\u00e9draogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9","family":"Kargougou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issa","family":"N\u00e9bi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siaka","family":"D\u00e9b\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amidou","family":"Diarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Bougouma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore B.","family":"Hounkpatin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayola Akim","family":"Adegnika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Lell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Joanny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabo Josiane","family":"Honkpehedji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Claude Dejon","family":"Agobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Esen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Ajua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Asoala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Anyorigiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana Akosua","family":"Ansah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Buwembo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edison","family":"Mworozi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musa","family":"Sekikubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismaela","family":"Abubakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalifa","family":"Bojang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramadhani","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Okech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawit A.","family":"Ejigu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9814","key":"10.1016\/j.vaccine.2016.07.041_b0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(12)60034-8","article-title":"Global malaria mortality between 1980 and 2010: a systematic analysis","volume":"379","author":"Murray","year":"2012","journal-title":"Lancet"},{"issue":"2\u20133","key":"10.1016\/j.vaccine.2016.07.041_b0010","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0165-2478(94)90118-X","article-title":"Mechanisms of defense against P. falciparum asexual blood stages in humans","volume":"41","author":"Druilhe","year":"1994","journal-title":"Immunol Lett"},{"key":"10.1016\/j.vaccine.2016.07.041_b0015","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/0035-9203(63)90058-0","article-title":"Treatment of East African P. falciparum malaria with West African gammaglobulin","volume":"57","author":"McGregor","year":"1963","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"192","key":"10.1016\/j.vaccine.2016.07.041_b0020","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/192733a0","article-title":"Gamma globulin and acquired immunity to human malaria","volume":"1961","author":"Cohen","year":"1961","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.vaccine.2016.07.041_b0025","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of phase 3 trial of RTS, S\/AS01 malaria vaccine in African children","volume":"365","author":"Agnandji","year":"2011","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.vaccine.2016.07.041_b0030","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","article-title":"A phase 3 trial of RTS, S\/AS01 malaria vaccine in African infants","volume":"367","author":"Agnandji","year":"2012","journal-title":"N Engl J Med"},{"issue":"9988","key":"10.1016\/j.vaccine.2016.07.041_b0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS, S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"Rts SCTP","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2016.07.041_b0040","doi-asserted-by":"crossref","first-page":"e4708","DOI":"10.1371\/journal.pone.0004708","article-title":"Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya","volume":"4","author":"Ogutu","year":"2009","journal-title":"PLoS ONE"},{"issue":"23","key":"10.1016\/j.vaccine.2016.07.041_b0045","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1016\/j.vaccine.2009.03.014","article-title":"A randomized controlled phase 2 trial of the blood stage AMA1-C1\/Alhydrogel malaria vaccine in children in Mali","volume":"27","author":"Sagara","year":"2009","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2016.07.041_b0050","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1086\/339342","article-title":"A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea","volume":"185","author":"Genton","year":"2002","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2016.07.041_b0055","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMoa1008115","article-title":"A field trial to assess a blood-stage malaria vaccine","volume":"365","author":"Thera","year":"2011","journal-title":"N Engl J Med"},{"issue":"6136","key":"10.1016\/j.vaccine.2016.07.041_b0060","doi-asserted-by":"crossref","first-page":"1232910","DOI":"10.1126\/science.1232910","article-title":"Accelerating next-generation vaccine development for global disease prevention","volume":"340","author":"Koff","year":"2013","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.vaccine.2016.07.041_b0065","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S1473-3099(15)00300-X","article-title":"Antibody titre as a surrogate of protection of the first malaria subunit vaccine, RTS, S\/AS01","volume":"15","author":"Tsuboi","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2016.07.041_b0070","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1056\/NEJMc1100670","article-title":"Protection against malaria by MSP3 candidate vaccine","volume":"365","author":"Sirima","year":"2011","journal-title":"N Engl J Med"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2016.07.041_b0075","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.vaccine.2003.09.017","article-title":"A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies","volume":"22","author":"Theisen","year":"2004","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2016.07.041_b0080","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1128\/IAI.68.5.2617-2620.2000","article-title":"Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal","volume":"68","author":"Oeuvray","year":"2000","journal-title":"Infect Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2016.07.041_b0085","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1371\/journal.pmed.0040320","article-title":"Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3","volume":"4","author":"Roussilhon","year":"2007","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.vaccine.2016.07.041_b0090","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1084\/jem.20121970","article-title":"Atypical and classical memory B cells produce Plasmodium falciparum neutralizing antibodies","volume":"210","author":"Muellenbeck","year":"2013","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.vaccine.2016.07.041_b0095","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/infdis\/jit185","article-title":"The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas","volume":"208","author":"Jepsen","year":"2013","journal-title":"J Infect Dis"},{"issue":"49","key":"10.1016\/j.vaccine.2016.07.041_b0100","doi-asserted-by":"crossref","first-page":"6862","DOI":"10.1016\/j.vaccine.2009.09.011","article-title":"Safety and immunogenicity of GMZ2 \u2013 a MSP3-GLURP fusion protein malaria vaccine candidate","volume":"27","author":"Esen","year":"2009","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2016.07.041_b0105","doi-asserted-by":"crossref","first-page":"e22525","DOI":"10.1371\/journal.pone.0022525","article-title":"A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children","volume":"6","author":"Belard","year":"2011","journal-title":"PLoS ONE"},{"issue":"41","key":"10.1016\/j.vaccine.2016.07.041_b0110","doi-asserted-by":"crossref","first-page":"6698","DOI":"10.1016\/j.vaccine.2010.07.085","article-title":"Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene, Gabon","volume":"28","author":"Mordmuller","year":"2010","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2016.07.041_b0115","doi-asserted-by":"crossref","first-page":"e86936","DOI":"10.1371\/journal.pone.0086936","article-title":"Malaria incidence in children in South-West Burkina Faso: comparison of active and passive case detection methods","volume":"9","author":"Tiono","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.07.041_b0120","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1186\/1756-0500-7-793","article-title":"Malariometric indices from Iganga, Uganda: baseline characterization in preparation of GMZ2 vaccine trial","volume":"7","author":"Kaddumukasa","year":"2014","journal-title":"BMC Res Notes"},{"issue":"2","key":"10.1016\/j.vaccine.2016.07.041_b0125","first-page":"242","article-title":"Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants","volume":"12","author":"Carvalho","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2016.07.041_b0130","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pt.2010.04.002","article-title":"Detecting signatures of balancing selection to identify targets of anti-parasite immunity","volume":"26","author":"Weedall","year":"2010","journal-title":"Trends Parasitol"},{"issue":"22","key":"10.1016\/j.vaccine.2016.07.041_b0135","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1016\/j.vaccine.2014.03.020","article-title":"A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages","volume":"32","author":"Theisen","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.07.041_b0140","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1741-7015-12-108","article-title":"Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria","volume":"12","author":"Osier","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2016.07.041_b0145","doi-asserted-by":"crossref","unstructured":"Tiendrebeogo RW, Adu B, Singh SK, Dziegiel MH, N\u00e9bi\u00e9 I, Sirima SB, et al. Antibody-dependent cellular inhibition is associated with reduced risk against febrile malaria in a longitudinal cohort study involving Ghanaian children. In: Open forum infectious diseases, vol. 2, no. 2, 2015 April 1.","DOI":"10.1093\/ofid\/ofv044"},{"issue":"37","key":"10.1016\/j.vaccine.2016.07.041_b0150","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1016\/j.vaccine.2013.06.042","article-title":"A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria","volume":"31","author":"Murungi","year":"2013","journal-title":"Vaccine"},{"issue":"60","key":"10.1016\/j.vaccine.2016.07.041_b0155","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1128\/iai.60.4.1473-1481.1992","article-title":"Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity","volume":"1992","author":"Bouharoun-Tayoun","year":"1992","journal-title":"Infect Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2016.07.041_b0160","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/infdis\/jit422","article-title":"Fc gamma receptor 3B (FCGR3B-c.233C>A-rs5030738) polymorphism modifies the protective effect of malaria specific antibodies in Ghanaian children","volume":"209","author":"Adu","year":"2014","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2016.07.041_b0165","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/infdis\/171.6.1576","article-title":"Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine","volume":"171","author":"Gordon","year":"1995","journal-title":"J Infect Dis"},{"issue":"9443","key":"10.1016\/j.vaccine.2016.07.041_b0170","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0140-6736(04)17223-1","article-title":"Efficacy of the RTS, S\/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial","volume":"364","author":"Alonso","year":"2004","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.vaccine.2016.07.041_b0175","doi-asserted-by":"crossref","first-page":"e7611","DOI":"10.1371\/journal.pone.0007611","article-title":"A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS, S malaria vaccine candidates in children in Gabon","volume":"4","author":"Lell","year":"2009","journal-title":"PLoS ONE"},{"issue":"17","key":"10.1016\/j.vaccine.2016.07.041_b0180","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1016\/j.vaccine.2011.02.022","article-title":"A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2\u2013a GLURP-MSP3 fusion protein malaria vaccine candidate","volume":"29","author":"Lousada-Dietrich","year":"2011","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16306259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16306259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T19:12:55Z","timestamp":1656270775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16306259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":36,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0264410X16306259"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.07.041","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726596565.793522476","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.07.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}